US4943587A
(en)
*
|
1988-05-19 |
1990-07-24 |
Warner-Lambert Company |
Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
|
US5112868A
(en)
*
|
1988-05-19 |
1992-05-12 |
Warner-Lambert Company |
Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition
|
US5068251A
(en)
*
|
1988-12-16 |
1991-11-26 |
Abbott Laboratories |
Lipoxygenase inhibiting compounds
|
US5212189A
(en)
*
|
1991-12-17 |
1993-05-18 |
Warner-Lambert Company |
Thiadiazole or oxadiazole analogs of fenamic acids containing substituted hydroxamate side chains as antiinflammatory agents
|
US6410729B1
(en)
|
1996-12-05 |
2002-06-25 |
Amgen Inc. |
Substituted pyrimidine compounds and methods of use
|
US6096753A
(en)
*
|
1996-12-05 |
2000-08-01 |
Amgen Inc. |
Substituted pyrimidinone and pyridone compounds and methods of use
|
US6022884A
(en)
|
1997-11-07 |
2000-02-08 |
Amgen Inc. |
Substituted pyridine compounds and methods of use
|
US6174901B1
(en)
|
1998-12-18 |
2001-01-16 |
Amgen Inc. |
Substituted pyridine and pyridazine compounds and methods of use
|
US6107291A
(en)
*
|
1997-12-19 |
2000-08-22 |
Amgen Inc. |
Azepine or larger medium ring derivatives and methods of use
|
US6335329B1
(en)
|
1997-12-19 |
2002-01-01 |
Amgen Inc. |
Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
|
US6187777B1
(en)
|
1998-02-06 |
2001-02-13 |
Amgen Inc. |
Compounds and methods which modulate feeding behavior and related diseases
|
US6514964B1
(en)
|
1999-09-27 |
2003-02-04 |
Amgen Inc. |
Fused cycloheptane and fused azacycloheptane compounds and their methods of use
|
US6849639B2
(en)
|
1999-12-14 |
2005-02-01 |
Amgen Inc. |
Integrin inhibitors and their methods of use
|
US6429223B1
(en)
*
|
2000-06-23 |
2002-08-06 |
Medinox, Inc. |
Modified forms of pharmacologically active agents and uses therefor
|
US6921762B2
(en)
|
2001-11-16 |
2005-07-26 |
Amgen Inc. |
Substituted indolizine-like compounds and methods of use
|
ATE493987T1
(de)
|
2002-05-22 |
2011-01-15 |
Amgen Inc |
Aminopyrimidin-derivate zur verwendung als vanilloid-rezeptor-liganden zur behandlung von schmerzen
|
US6908935B2
(en)
|
2002-05-23 |
2005-06-21 |
Amgen Inc. |
Calcium receptor modulating agents
|
US7176322B2
(en)
|
2002-05-23 |
2007-02-13 |
Amgen Inc. |
Calcium receptor modulating agents
|
CA2493667C
(en)
|
2002-08-08 |
2010-04-27 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
US7504396B2
(en)
|
2003-06-24 |
2009-03-17 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
US7442698B2
(en)
|
2003-07-24 |
2008-10-28 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
US7582631B2
(en)
|
2004-01-14 |
2009-09-01 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
US7429616B2
(en)
|
2005-07-15 |
2008-09-30 |
Board Of Regents, University Of Texas System |
Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds
|
US7754717B2
(en)
|
2005-08-15 |
2010-07-13 |
Amgen Inc. |
Bis-aryl amide compounds and methods of use
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
JP5160535B2
(ja)
|
2006-03-29 |
2013-03-13 |
ノバルティス アーゲー |
選択的ヒドロキサメート骨格mmp阻害剤
|
ATE540681T1
(de)
|
2006-06-26 |
2012-01-15 |
Amgen Inc |
Verfahren zur behandlung von atherosklerose
|
WO2008008493A2
(en)
|
2006-07-14 |
2008-01-17 |
Amgen Inc. |
Alkyne-substituted pyridone compounds and methods of use
|
JP5042311B2
(ja)
|
2006-07-20 |
2012-10-03 |
ノバルティス アーゲー |
Cetp阻害剤としてのアミノピペリジン誘導体
|
ES2344760T3
(es)
|
2006-07-20 |
2010-09-06 |
Amgen Inc. |
Compuestos de piridona sustituidos y metodo de uso.
|
WO2008011110A2
(en)
|
2006-07-20 |
2008-01-24 |
Amgen Inc. |
Di-amino-substituted heterocyclic compounds and methods of use
|
UA98955C2
(ru)
|
2007-03-23 |
2012-07-10 |
Амген Инк. |
Гетероциклические соединения и их применение
|
WO2009059943A1
(en)
|
2007-11-05 |
2009-05-14 |
Novartis Ag |
4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
|
PL2229356T3
(pl)
|
2007-12-03 |
2012-03-30 |
Novartis Ag |
1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
|
CN102036953B
(zh)
|
2008-03-24 |
2015-05-06 |
诺华股份有限公司 |
基于芳基磺酰胺的基质金属蛋白酶抑制剂
|
ES2397934T3
(es)
|
2008-12-17 |
2013-03-12 |
Amgen Inc. |
Compuestos de aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10
|
WO2010085968A1
(en)
|
2008-12-30 |
2010-08-05 |
European Molecular Biology Laboratory (Embl) |
Toluidine sulfonamides and their use as hif-inhibitors
|
WO2010075869A1
(en)
|
2008-12-30 |
2010-07-08 |
European Molecular Biology Laboratory (Embl) |
Toluidine sulfonamides and their use
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
BRPI1010600A2
(pt)
|
2009-05-15 |
2016-03-15 |
Novartis Ag |
aril piridina como inibidores de aldosterona sintase
|
MA33364B1
(fr)
|
2009-05-28 |
2012-06-01 |
Novartis Ag |
Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
|
EA019511B1
(ru)
|
2009-05-28 |
2014-04-30 |
Новартис Аг |
Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
|
CA2765823A1
(en)
|
2009-06-25 |
2010-12-29 |
Amgen Inc. |
Tricyclic heterocyclic compounds as mediators of p13k activity
|
EP2445898A2
(en)
|
2009-06-25 |
2012-05-02 |
Amgen, Inc |
4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors
|
EP2445900B1
(en)
|
2009-06-25 |
2016-03-02 |
Amgen, Inc |
Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
|
JP2012531436A
(ja)
|
2009-06-25 |
2012-12-10 |
アムジエン・インコーポレーテツド |
複素環式化合物およびそれらのpi3k活性阻害剤としての使用
|
UY32799A
(es)
|
2009-07-24 |
2011-02-28 |
Novartis Ag |
Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
|
JP2013503129A
(ja)
|
2009-08-26 |
2013-01-31 |
ノバルティス アーゲー |
テトラ−置換ヘテロアリール化合物ならびにmdm2および/またはmdm4モジュレーターとしてのそれらの使用
|
NZ598455A
(en)
|
2009-09-03 |
2014-03-28 |
Allergan Inc |
Compounds as tyrosine kinase modulators
|
US9340555B2
(en)
|
2009-09-03 |
2016-05-17 |
Allergan, Inc. |
Compounds as tyrosine kinase modulators
|
BR112012004836A2
(pt)
|
2009-09-04 |
2019-09-24 |
Novartis Ag |
pirazinilpiridinas úteis para o tratamento de doenças proliferativas
|
CA2771568A1
(en)
|
2009-09-04 |
2011-03-10 |
Novartis Ag |
Heteroaryl compounds as kinase inhibitors
|
CA2771563A1
(en)
|
2009-09-04 |
2011-03-10 |
Novartis Ag |
Bipyridines useful for the treatment of proliferative diseases
|
AR078770A1
(es)
|
2009-10-27 |
2011-11-30 |
Elara Pharmaceuticals Gmbh |
Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
|
EP2993169B1
(en)
|
2009-11-17 |
2017-12-20 |
Novartis AG |
Aryl-pyridine derivatives as aldosterone synthase inhibitors
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
EP2507234B1
(en)
|
2009-11-30 |
2014-03-12 |
Novartis AG |
Imidazole derivatives as aldosterone synthase inhibitors
|
WO2011073316A1
(en)
|
2009-12-18 |
2011-06-23 |
Novartis Ag |
4-aryl-butane-1,3-diamides
|
MX2012006953A
(es)
|
2009-12-18 |
2012-10-09 |
Amgen Inc |
Compuestos heterociclicos y sus usos.
|
EP2516437B1
(en)
|
2009-12-21 |
2014-01-29 |
Novartis AG |
Disubstituted heteroaryl-fused pyridines
|
CN102762567A
(zh)
|
2009-12-21 |
2012-10-31 |
诺瓦提斯公司 |
作为食欲肽受体拮抗剂的二氮杂-螺[5.5]十一烷类
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
AR080056A1
(es)
|
2010-02-01 |
2012-03-07 |
Novartis Ag |
Derivados de ciclohexil-amida como antagonistas de los receptores de crf
|
WO2011092290A1
(en)
|
2010-02-01 |
2011-08-04 |
Novartis Ag |
Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
|
WO2011095450A1
(en)
|
2010-02-02 |
2011-08-11 |
Novartis Ag |
Cyclohexyl amide derivatives as crf receptor antagonists
|
US8791100B2
(en)
|
2010-02-02 |
2014-07-29 |
Novartis Ag |
Aryl benzylamine compounds
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
UY33226A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
UY33304A
(es)
|
2010-04-02 |
2011-10-31 |
Amgen Inc |
Compuestos heterocíclicos y sus usos
|
US8324239B2
(en)
|
2010-04-21 |
2012-12-04 |
Novartis Ag |
Furopyridine compounds and uses thereof
|
MX2012013127A
(es)
|
2010-05-13 |
2012-11-30 |
Amgen Inc |
Compuestos heteroariloxiheterociclilo como inhibidores pde10.
|
KR101564806B1
(ko)
|
2010-05-13 |
2015-10-30 |
암젠 인크 |
Pde10 저해제로서 유용한 질소 헤테로시클릭 화합물
|
AU2011253143A1
(en)
|
2010-05-13 |
2012-12-06 |
Amgen Inc. |
Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
|
AU2011253058A1
(en)
|
2010-05-13 |
2012-12-06 |
Amgen Inc. |
Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
|
JP2013532149A
(ja)
|
2010-06-17 |
2013-08-15 |
ノバルティス アーゲー |
ピペリジニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体
|
JP2013528635A
(ja)
|
2010-06-17 |
2013-07-11 |
ノバルティス アーゲー |
ビフェニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体
|
UY33469A
(es)
|
2010-06-29 |
2012-01-31 |
Irm Llc Y Novartis Ag |
Composiciones y metodos para modular la via de señalizacion de wnt
|
AU2011272857A1
(en)
|
2010-06-30 |
2013-01-10 |
Amgen Inc. |
Quinolines as P13K inhibitors
|
CA2803358A1
(en)
|
2010-06-30 |
2012-01-05 |
Amgen Inc. |
Heterocyclic compounds and their use as inhibitors of pi3k activity
|
MX2012015143A
(es)
|
2010-06-30 |
2013-07-03 |
Amgen Inc |
Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta.
|
US8759371B2
(en)
|
2010-07-01 |
2014-06-24 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
AU2011272853A1
(en)
|
2010-07-01 |
2013-01-10 |
Amgen Inc. |
Heterocyclic compounds and their use as inhibitors of PI3K activity
|
JP2013533884A
(ja)
|
2010-07-02 |
2013-08-29 |
アムジエン・インコーポレーテツド |
Pi3k活性阻害剤としての複素環化合物およびそれらの使用
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
SG178311A1
(en)
|
2010-07-13 |
2012-03-29 |
Novartis Ag |
Oxazine derivatives and their use in the treatment of neurological disorders
|
UA109786C2
(xx)
|
2010-07-14 |
2015-10-12 |
|
Гетероциклічні сполуки як агоністи ір-рецептора
|
BR112013001516A2
(pt)
|
2010-07-22 |
2016-06-07 |
Novartis Ag |
compostos de tiofeno 2,3,5-trissubstituídos e empregos destes
|
US9290485B2
(en)
|
2010-08-04 |
2016-03-22 |
Novartis Ag |
N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
|
PE20131377A1
(es)
|
2010-09-13 |
2013-11-30 |
Novartis Ag |
Triazina-oxadiazoles
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
AR083058A1
(es)
|
2010-09-20 |
2013-01-30 |
Envivo Pharmaceuticals Inc |
Compuestos de estructura de imidazotriazinona
|
US20120101110A1
(en)
|
2010-10-26 |
2012-04-26 |
Sangamesh Badiger |
Diaza-spiro[5.5]undecanes
|
JP2013541591A
(ja)
|
2010-11-04 |
2013-11-14 |
アムジエン・インコーポレーテツド |
複素環化合物およびそれらの使用
|
US8993631B2
(en)
|
2010-11-16 |
2015-03-31 |
Novartis Ag |
Method of treating contrast-induced nephropathy
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
AU2011329806A1
(en)
|
2010-11-17 |
2013-05-30 |
Amgen Inc. |
Quinoline derivatives as PIK3 inhibitors
|
AU2011338389A1
(en)
|
2010-12-09 |
2013-06-13 |
Amgen Inc. |
Bicyclic compounds as Pim inhibitors
|
CU24152B1
(es)
|
2010-12-20 |
2016-02-29 |
Irm Llc |
1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
|
EP2655369A1
(en)
|
2010-12-20 |
2013-10-30 |
Irm Llc |
Compositions and methods for modulating farnesoid x receptors
|
JP2014500318A
(ja)
|
2010-12-20 |
2014-01-09 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
ファルネソイドx受容体を調節するための組成物および方法
|
WO2012087784A1
(en)
|
2010-12-23 |
2012-06-28 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
KR20140027090A
(ko)
|
2011-01-04 |
2014-03-06 |
노파르티스 아게 |
연령-관련 황반 변성 (amd)의 치료에 유용한 인돌 화합물 또는 그의 유사체
|
US20140128385A1
(en)
|
2011-01-13 |
2014-05-08 |
Novartis Ag |
Bace-2 inhibitors for the treatment of metabolic disorders
|
WO2012101066A1
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
Pyridine biaryl amine compounds and their uses
|
WO2012101065A2
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
Pyrimidine biaryl amine compounds and their uses
|
WO2012101064A1
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
|
WO2012101063A1
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
N-acyl pyridine biaryl compounds and their uses
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
CA2830780A1
(en)
|
2011-03-22 |
2012-09-27 |
Amgen Inc. |
Azole compounds as pim inhibitors
|
WO2012130306A1
(en)
|
2011-03-30 |
2012-10-04 |
Elara Pharmaceuticals Gmbh |
Bicyclic 2,3-dihyrdobenzazine compounds for use in therapy
|
US20140221354A1
(en)
|
2011-03-31 |
2014-08-07 |
Emblem Technology Transfer Gmbh |
IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY
|
WO2012130314A1
(en)
|
2011-03-31 |
2012-10-04 |
Elara Pharmaceuticals Gmbh |
Composition comprising docetaxel
|
WO2012138648A1
(en)
|
2011-04-06 |
2012-10-11 |
Irm Llc |
Compositions and methods for modulating lpa receptors
|
EP2702063A1
(en)
|
2011-04-29 |
2014-03-05 |
Amgen Inc. |
Bicyclic pyridazine compounds as pim inhibitors
|
MX2013015058A
(es)
|
2011-06-24 |
2014-01-20 |
Amgen Inc |
Antagonistas de melastatina 8 de potencial receptor transitorio y su uso en tratamientos.
|
CA2839699A1
(en)
|
2011-06-24 |
2012-12-27 |
Amgen Inc. |
Trpm8 antagonists and their use in treatments
|
US8846656B2
(en)
|
2011-07-22 |
2014-09-30 |
Novartis Ag |
Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
|
WO2013057711A1
(en)
|
2011-10-21 |
2013-04-25 |
Novartis Ag |
Quinazoline derivatives as pi3k modulators
|
EP2802582A1
(en)
|
2012-01-13 |
2014-11-19 |
Novartis AG |
Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
|
US20150005311A1
(en)
|
2012-01-13 |
2015-01-01 |
Novartis Ag |
IP receptor agonist heterocyclic compounds
|
WO2013105058A1
(en)
|
2012-01-13 |
2013-07-18 |
Novartis Ag |
7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
|
EP2802589B1
(en)
|
2012-01-13 |
2016-01-06 |
Novartis AG |
Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
|
WO2013105065A1
(en)
|
2012-01-13 |
2013-07-18 |
Novartis Ag |
Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
|
TW201348226A
(zh)
|
2012-02-28 |
2013-12-01 |
Amgen Inc |
作為pim抑制劑之醯胺
|
TW201348231A
(zh)
|
2012-02-29 |
2013-12-01 |
Amgen Inc |
雜雙環化合物
|
EP2828262A4
(en)
|
2012-03-19 |
2015-09-23 |
Forum Pharmaceuticals Inc |
IMIDAZOTRIAZINONVERBINDUNGEN
|
PL2834231T3
(pl)
|
2012-04-04 |
2016-07-29 |
Amgen Inc |
Związki heterocykliczne i ich zastosowanie
|
EA027113B1
(ru)
|
2012-05-04 |
2017-06-30 |
Новартис Аг |
Регуляторы пути комплемента и их применение
|
US20150152083A1
(en)
|
2012-06-06 |
2015-06-04 |
Irm Llc, A Delaware Limited Liability Company |
Compounds and Compositions for Modulating EGFR Activity
|
JO3300B1
(ar)
|
2012-06-06 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات لتعديل نشاط egfr
|
UY34858A
(es)
|
2012-06-14 |
2013-11-29 |
Amgen Inc |
Compuestos de azetidina y piperidina útiles como inhibidores de pde10
|
CN104662015B
(zh)
|
2012-06-20 |
2017-03-29 |
诺华股份有限公司 |
补体途径调节剂及其用途
|
US9815819B2
(en)
|
2012-06-28 |
2017-11-14 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
CN104583193A
(zh)
|
2012-06-28 |
2015-04-29 |
诺华股份有限公司 |
吡咯烷衍生物及其作为补体途径调节剂的用途
|
EP2867224B1
(en)
|
2012-06-28 |
2017-07-26 |
Novartis AG |
Pyrrolidine derivatives and their use as complement pathway modulators
|
CN104379579B
(zh)
|
2012-06-28 |
2017-03-08 |
诺华股份有限公司 |
吡咯烷衍生物及其作为补体途径调节剂的用途
|
EP2867227B1
(en)
|
2012-06-28 |
2018-11-21 |
Novartis AG |
Complement pathway modulators and uses thereof
|
CN104619698B
(zh)
|
2012-06-28 |
2016-08-31 |
诺华股份有限公司 |
吡咯烷衍生物及其作为补体途径调节剂的用途
|
BR112015000578A2
(pt)
|
2012-07-12 |
2017-06-27 |
Novartis Ag |
moduladores da via do complemento e usos dos mesmos
|
WO2014022752A1
(en)
|
2012-08-03 |
2014-02-06 |
Amgen Inc. |
Macrocycles as pim inhibitors
|
WO2014023329A1
(en)
|
2012-08-06 |
2014-02-13 |
Life And Brain Gmbh |
Niclosamide and its derivatives for use in the treatment of solid tumors
|
US20150210717A1
(en)
|
2012-09-13 |
2015-07-30 |
Baden-Württemberg Stiftung Gmbh |
Specific inhibitors of protein p21 as therapeutic agents
|
JP2016507582A
(ja)
|
2013-02-13 |
2016-03-10 |
ノバルティス アーゲー |
Ip受容体アゴニスト複素環式化合物
|
SI2956464T1
(en)
|
2013-02-14 |
2018-08-31 |
Novartis Ag |
Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (neutral endopeptidases)
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
ES2761587T3
(es)
|
2013-08-07 |
2020-05-20 |
Friedrich Miescher Institute For Biomedical Res |
Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
|
EP2924026A1
(en)
|
2014-03-28 |
2015-09-30 |
Novartis Tiergesundheit AG |
Aminosulfonylmethylcyclohexanes as JAK inhibitors
|
WO2016088082A1
(en)
|
2014-12-05 |
2016-06-09 |
Novartis Ag |
Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
|
US10407398B2
(en)
|
2015-03-24 |
2019-09-10 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Inhibitors of Pseudomonas aeruginosa LecB
|
EP3288948B1
(en)
|
2015-04-30 |
2019-11-20 |
Novartis AG |
Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors
|
EP3337463A4
(en)
|
2015-08-19 |
2019-04-03 |
Vivus, Inc. |
PHARMACEUTICAL FORMULATIONS
|
CN105418480B
(zh)
*
|
2015-11-16 |
2019-05-10 |
青岛大学 |
2-(1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1氢-吲哚-3-基)-n-羟基乙酰胺的制备和应用
|
CN108602804A
(zh)
|
2015-12-18 |
2018-09-28 |
美国安进公司 |
烷基二氢喹啉磺酰胺化合物
|
AU2016369653B2
(en)
|
2015-12-18 |
2021-02-04 |
Amgen Inc |
Alkynyl dihydroquinoline sulfonamide compounds
|
US11078191B2
(en)
|
2017-02-10 |
2021-08-03 |
Novartis Ag |
1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)pyrimidin-2-yl)-1H-pyrazol-4-ol and use thereof in the treatment of cancer
|
EP3638668A1
(en)
|
2017-06-14 |
2020-04-22 |
European Molecular Biology Laboratory |
Bicyclic heteroaromatic urea or carbamate compounds for use in therapy
|
EP3638667A1
(en)
|
2017-06-14 |
2020-04-22 |
European Molecular Biology Laboratory |
Bicyclic heteroaromatic amide compounds for use in therapy
|
EP3638662A1
(en)
|
2017-06-14 |
2020-04-22 |
European Molecular Biology Laboratory |
Benzofuran ureas or carbamates and heteroaromatic analogues thereof for use in therapy
|
AU2018285449A1
(en)
|
2017-06-14 |
2019-12-19 |
European Molecular Biology Laboratory |
Benzofuran amides and heteroaromatic analogues thereof for use in therapy
|
AU2019219057B2
(en)
|
2018-02-06 |
2022-11-24 |
Universität Heidelberg |
FAP inhibitor
|
WO2019154859A1
(en)
|
2018-02-06 |
2019-08-15 |
Universität Heidelberg |
Fap inhibitor
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
GB201811825D0
(en)
|
2018-07-19 |
2018-09-05 |
Benevolentai Bio Ltd |
Organic compounds
|
GB201813791D0
(en)
|
2018-08-23 |
2018-10-10 |
Benevolental Bio Ltd |
Organic compounds
|
TWI844602B
(zh)
|
2018-12-20 |
2024-06-11 |
美商安進公司 |
Kif18a抑制劑
|
WO2020132649A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
CA3123042A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
EP3898592A1
(en)
|
2018-12-20 |
2021-10-27 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
JP2022542967A
(ja)
|
2019-08-02 |
2022-10-07 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
MX2022001296A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
AU2020325115A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
Pyridine derivatives as KIF18A inhibitors
|
JP2022542394A
(ja)
|
2019-08-02 |
2022-10-03 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤として有用なヘテロアリールアミド
|
US20220402960A1
(en)
|
2019-11-05 |
2022-12-22 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Bivalent leca inhibitors targeting biofilm formation of pseudomonas aeruginosa
|
IL294687A
(en)
|
2020-01-22 |
2022-09-01 |
Benevolentai Bio Ltd |
Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds
|
KR20220131267A
(ko)
|
2020-01-22 |
2022-09-27 |
베네볼런트에이아이 바이오 리미티드 |
약제학적 조성물 및 이의 용도
|
IL297242A
(en)
|
2020-04-14 |
2022-12-01 |
Amgen Inc |
kif18a inhibitors for the treatment of neoplastic diseases
|
WO2021234181A1
(en)
|
2020-05-22 |
2021-11-25 |
Universität Heidelberg |
Use of fap inhibitor in a method of diagnosis
|
JP2021195367A
(ja)
|
2020-06-10 |
2021-12-27 |
アムジエン・インコーポレーテツド |
シクロプロピルジヒドロキノリンスルホンアミド化合物
|
JP2021195368A
(ja)
|
2020-06-10 |
2021-12-27 |
アムジエン・インコーポレーテツド |
シクロブチルジヒドロキノリンスルホンアミド化合物
|
US20240025849A1
(en)
|
2020-08-26 |
2024-01-25 |
Max Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Inhibitors of no production
|
TW202237095A
(zh)
|
2020-12-03 |
2022-10-01 |
德商艾斯巴赫生物有限公司 |
Alc1抑制劑及與parpi之協同性
|
JP2023554396A
(ja)
|
2020-12-17 |
2023-12-27 |
トラスティーズ オブ タフツ カレッジ |
Fap活性化ラジオセラノスティクスおよび関連する使用
|
WO2023073222A1
(en)
|
2021-10-29 |
2023-05-04 |
Eisbach Bio Gmbh |
Inhibitors of viral helicases binding to a novel allosteric binding site
|
TW202348228A
(zh)
|
2022-02-24 |
2023-12-16 |
德商艾斯巴赫生物有限公司 |
病毒組合療法
|
WO2023213833A1
(en)
|
2022-05-02 |
2023-11-09 |
Eisbach Bio Gmbh |
Use of alc1 inhibitors and synergy with parpi
|
WO2024022332A1
(en)
|
2022-07-26 |
2024-02-01 |
Shanghai Sinotau Biotech. Co., Ltd |
Fap inhibitors
|